NCT06419413 A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
| NCT ID | NCT06419413 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 355 participants |
| Start Date | 2024-01-08 |
| Primary Completion | 2026-10-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 355 participants in total. It began in 2024-01-08 with a primary completion date of 2026-10-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese Population
Eligibility Criteria
Inclusion Criteria: * Age 18 to 75 years of age * acceptable FEV1 (according to ATS and ERS) * compliance with study procedures All Asthma Cohorts * physician diagnosed Asthma greater or equal to 3 months prior to screening visit Exclusion Criteria: * history of alcohol or drug abuse within the past year * pregnant at time of an assessment * has an altered mental status at the time of informed consent * receipt marketed or investigational biologic(s) within 3 months or 5 half-lives prior to visit 1, whichever is longer * history or current upper or lower respiratory infection or symptoms within 2 weeks of baseline assessments * terminal diseases and/or organ failure or participants otherwise considered not appropriate for the study participation * Receipt LTRAs or 5-lipoxygenase (5-LO) inhibitors (eg zileuton and montelukast) within 1 month or 5 half-lives prior to baseline, whichever is longer.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06419413 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06419413 currently recruiting?
Yes, NCT06419413 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT06419413 trial being conducted?
This trial is being conducted at Chengdu, China, Beijing, China, Changsha, China, Dongguan, China and 11 additional locations.
Who is sponsoring the NCT06419413 clinical trial?
NCT06419413 is sponsored by AstraZeneca. The trial plans to enroll 355 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.